These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. Girotti MR; Pedersen M; Sanchez-Laorden B; Viros A; Turajlic S; Niculescu-Duvaz D; Zambon A; Sinclair J; Hayes A; Gore M; Lorigan P; Springer C; Larkin J; Jorgensen C; Marais R Cancer Discov; 2013 Feb; 3(2):158-67. PubMed ID: 23242808 [TBL] [Abstract][Full Text] [Related]
8. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib. Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428 [TBL] [Abstract][Full Text] [Related]
10. BET and BRAF inhibitors act synergistically against BRAF-mutant melanoma. Paoluzzi L; Hanniford D; Sokolova E; Osman I; Darvishian F; Wang J; Bradner JE; Hernando E Cancer Med; 2016 Jun; 5(6):1183-93. PubMed ID: 27169980 [TBL] [Abstract][Full Text] [Related]
11. Optimising the combination dosing strategy of abemaciclib and vemurafenib in BRAF-mutated melanoma xenograft tumours. Tate SC; Burke TF; Hartman D; Kulanthaivel P; Beckmann RP; Cronier DM Br J Cancer; 2016 Mar; 114(6):669-79. PubMed ID: 26978007 [TBL] [Abstract][Full Text] [Related]
12. Induction of Therapeutic Senescence in Vemurafenib-Resistant Melanoma by Extended Inhibition of CDK4/6. Yoshida A; Lee EK; Diehl JA Cancer Res; 2016 May; 76(10):2990-3002. PubMed ID: 26988987 [TBL] [Abstract][Full Text] [Related]
13. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Sun C; Wang L; Huang S; Heynen GJ; Prahallad A; Robert C; Haanen J; Blank C; Wesseling J; Willems SM; Zecchin D; Hobor S; Bajpe PK; Lieftink C; Mateus C; Vagner S; Grernrum W; Hofland I; Schlicker A; Wessels LF; Beijersbergen RL; Bardelli A; Di Nicolantonio F; Eggermont AM; Bernards R Nature; 2014 Apr; 508(7494):118-22. PubMed ID: 24670642 [TBL] [Abstract][Full Text] [Related]
14. Mutational activation of BRAF confers sensitivity to transforming growth factor beta inhibitors in human cancer cells. Spender LC; Ferguson GJ; Liu S; Cui C; Girotti MR; Sibbet G; Higgs EB; Shuttleworth MK; Hamilton T; Lorigan P; Weller M; Vincent DF; Sansom OJ; Frame M; Dijke PT; Marais R; Inman GJ Oncotarget; 2016 Dec; 7(50):81995-82012. PubMed ID: 27835901 [TBL] [Abstract][Full Text] [Related]
15. Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance. Martin CA; Cullinane C; Kirby L; Abuhammad S; Lelliott EJ; Waldeck K; Young RJ; Brajanovski N; Cameron DP; Walker R; Sanij E; Poortinga G; Hannan RD; Pearson RB; Hicks RJ; McArthur GA; Sheppard KE Int J Cancer; 2018 May; 142(10):2139-2152. PubMed ID: 29243224 [TBL] [Abstract][Full Text] [Related]
16. Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma. Ma XH; Piao SF; Dey S; McAfee Q; Karakousis G; Villanueva J; Hart LS; Levi S; Hu J; Zhang G; Lazova R; Klump V; Pawelek JM; Xu X; Xu W; Schuchter LM; Davies MA; Herlyn M; Winkler J; Koumenis C; Amaravadi RK J Clin Invest; 2014 Mar; 124(3):1406-17. PubMed ID: 24569374 [TBL] [Abstract][Full Text] [Related]
17. Vemurafenib resistance increases melanoma invasiveness and modulates the tumor microenvironment by MMP-2 upregulation. Sandri S; Faião-Flores F; Tiago M; Pennacchi PC; Massaro RR; Alves-Fernandes DK; Berardinelli GN; Evangelista AF; de Lima Vazquez V; Reis RM; Maria-Engler SS Pharmacol Res; 2016 Sep; 111():523-533. PubMed ID: 27436149 [TBL] [Abstract][Full Text] [Related]
18. ACY-1215 accelerates vemurafenib induced cell death of BRAF-mutant melanoma cells via induction of ER stress and inhibition of ERK activation. Peng U; Wang Z; Pei S; Ou Y; Hu P; Liu W; Song J Oncol Rep; 2017 Feb; 37(2):1270-1276. PubMed ID: 28035401 [TBL] [Abstract][Full Text] [Related]
19. Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimetics. Frederick DT; Salas Fragomeni RA; Schalck A; Ferreiro-Neira I; Hoff T; Cooper ZA; Haq R; Panka DJ; Kwong LN; Davies MA; Cusack JC; Flaherty KT; Fisher DE; Mier JW; Wargo JA; Sullivan RJ PLoS One; 2014; 9(7):e101286. PubMed ID: 24983357 [TBL] [Abstract][Full Text] [Related]
20. The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms. Paraiso KH; Haarberg HE; Wood E; Rebecca VW; Chen YA; Xiang Y; Ribas A; Lo RS; Weber JS; Sondak VK; John JK; Sarnaik AA; Koomen JM; Smalley KS Clin Cancer Res; 2012 May; 18(9):2502-14. PubMed ID: 22351686 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]